Janet Leeds - Penumbra Lead Independent Director
| PEN Stock | USD 291.84 10.22 3.63% |
Director
Ms. Janet Leeds is Independent Director of the Company. Ms. Leeds has served on the Board since January 2019. Ms. Leeds has held a number of leadership and consulting roles in academic healthcare settings over more than thirty years. Currently, Ms. Leeds serves as an Administrative Director at the Seattle Cancer Care Alliance, a cancer center comprising Fred Hutchinson Cancer Research Center, Seattle Childrens Hospital and UW Medicine. From 2005 to 2009, Ms. Leeds served as the Administrator for the Fred HutchinsonUniversity of Washington Cancer Consortium. From 2000 to 2005, Ms. Leeds served as the Director of Planning at the Fred Hutchinson Cancer Research Center. From 1996 to 2000, Ms. Leeds served in various positions that were instrumental to the formation and development of the SCCA. Prior to that, from 1987 to 1995, Ms. Leeds held management consultant positions of increasing responsibility at ECG Management Consultants, where she primarily consulted with academic medical centers since 2019.
| Age | 58 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | One Penumbra Place, Alameda, CA, United States, 94502 |
| Phone | 510 748 3200 |
| Web | https://www.penumbrainc.com |
Penumbra Management Efficiency
The company has Return on Asset of 0.0484 % which means that on every $100 spent on assets, it made $0.0484 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.012 %, implying that it generated $0.012 on every 100 dollars invested. Penumbra's management efficiency ratios could be used to measure how well Penumbra manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of February 2025, Return On Equity is likely to grow to 0.01, while Return On Tangible Assets are likely to drop 0.01. At this time, Penumbra's Non Current Assets Total are very stable compared to the past year. As of the 27th of February 2025, Non Currrent Assets Other is likely to grow to about 148.3 M, while Total Assets are likely to drop about 820.4 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| William Summers | Integer Holdings Corp | 70 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| David Bronson | CONMED | 67 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Brian Concannon | CONMED | 62 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Casey Tansey | Inspire Medical Systems | 63 | |
| Jerome Lande | CONMED | 45 | |
| Gary Ellis | Inspire Medical Systems | 64 | |
| Charles Farkas | CONMED | 68 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| Shawn McCormick | Inspire Medical Systems | 56 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Martha Aronson | CONMED | 53 | |
| John Workman | CONMED | 69 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Dana Mead | Inspire Medical Systems | 61 | |
| Michelle Brennan | Masimo | 58 | |
| Georgia GarinoisMelenikiotou | Inspire Medical Systems | 60 | |
| Shelley Broader | Inspire Medical Systems | 56 | |
Management Performance
| Return On Equity | 0.012 | ||||
| Return On Asset | 0.0484 |
Penumbra Leadership Team
Elected by the shareholders, the Penumbra's board of directors comprises two types of representatives: Penumbra inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Penumbra. The board's role is to monitor Penumbra's management team and ensure that shareholders' interests are well served. Penumbra's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Penumbra's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ben Tompkins, Executive Development | ||
| Surbhi Sarna, Independent Director | ||
| Bridget ORourke, Independent Director | ||
| Adam Elsesser, Chairman of the Board, Chief Executive Officer | ||
| James Pray, President International | ||
| Shruthi Narayan, Executive Interventional | ||
| Gita Barry, President Healthcare | ||
| Holly Sit, Director Development | ||
| Lynn Rothman, Executive Vice President, Chief Business Officer | ||
| Arani MD, CoFounder Director | ||
| Pankaj Tiwari, Executive Officer | ||
| Harpreet Grewal, Independent Director | ||
| Maggie Yuen, Chief Financial Officer | ||
| Jee HamlynHarris, Investor Officer | ||
| Don Kassing, Presiding Independent Director | ||
| Adam JD, Chairman, CoFounder | ||
| Ben Sorci, Executive Operations | ||
| Lambert Shiu, Chief Accounting Officer | ||
| Johanna Roberts, Executive Vice President General Counsel, Secretary | ||
| MD FSIR, Chief Officer | ||
| Jason Mills, Executive Strategy | ||
| Thomas Wilder, Independent Director | ||
| Sandra Lesenfants, President Interventional | ||
| Arani Bose, Executive Director and Chief Innovator | ||
| Johanna JD, General VP | ||
| Janet Leeds, Lead Independent Director |
Penumbra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Penumbra a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.012 | ||||
| Return On Asset | 0.0484 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 11.12 B | ||||
| Shares Outstanding | 38.52 M | ||||
| Shares Owned By Insiders | 3.97 % | ||||
| Shares Owned By Institutions | 92.19 % | ||||
| Number Of Shares Shorted | 1.43 M | ||||
| Price To Earning | 191.13 X |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Penumbra. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Penumbra Stock, please use our How to Invest in Penumbra guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Penumbra. If investors know Penumbra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Penumbra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share 0.38 | Revenue Per Share | Quarterly Revenue Growth 0.108 | Return On Assets |
The market value of Penumbra is measured differently than its book value, which is the value of Penumbra that is recorded on the company's balance sheet. Investors also form their own opinion of Penumbra's value that differs from its market value or its book value, called intrinsic value, which is Penumbra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Penumbra's market value can be influenced by many factors that don't directly affect Penumbra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Penumbra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Penumbra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Penumbra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.